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A concise and stereocontrolled synthesis of rosuvastatin calcium has been accomplished, with the key
steps including a Keck enantioselective allylation of chloroacetaldehyde with allyltributylstannane to
install 5R-stereocenter and a VO(acac)2-catalyzed syn-diastereoselective epoxidation of (S)-1-
chloropent-4-en-2-ol to set the requisite 3R-chirality.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Rosuvastatin calcium (Crestor, 1, Fig. 1) was marketed as a 3-
hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase in-
hibitor by AstraZeneca in 2003, and has been billed as a ‘super-
statin’ because of its pronounced ability to reduce low-density li-
poprotein cholesterol levels and increase high-density lipoprotein
cholesterol compared with existing agents.2 The development of
a concise synthetic strategy for rosuvastatin calcium is therefore
highly desired. One of the most commonly used strategies for
construction of pyrimidine core attached to (3R,5R)-3,5-dihydroxy-
heptenoic acid in 1 is adopted a Wittig-type oleﬁnation of the ylide
2with the C6 side chain aldehyde 3 (Fig. 1).3 The efﬁcient assembly
of 3R-syn-3,5-diol subunit is the key issue for the synthesis of 3.
Considerable synthetic efforts have been directed towards the de-
velopment of strategies for construction of 3, and have culminated
in several new methods based on chiral pool synthesis,4 asym-
metric catalysis,5 or the use of chiral auxiliary6 or chemoenzymatic
process.7 One of the major industrial processes for construction of
C6 side chain involves Blaise condensation of a C2 synthonwith a C4
synthon (starting from (S)-epichlorohydrin).4hej One of the major
limitations of this route, however, is the use of Narasaka reduction
to introduce the second stereogenic center, because this reactionFig. 1. The chemical structures of 1, 2, and 3.
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Table 1
Optimization of Keck asymmetric allylation of chloroacetaldehydea
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78 C). Herein, we describe the development of an efﬁcient and
alternative strategy for the synthesis of 1, which avoids the use of
Narasaka reduction.Entry Catalyst Temp (C) Time (h) Yieldb (%) eec (%)
1 (S)-BINOL, Ti(OiPr)4 20 96 67 94
2 (S)-VANOL, Ti(OiPr)4 0 96 41 54
3 (R)-VAPOL, Ti(OiPr)4 0 96 37 46
4 (S)-BINOL, FeCl3 0 72 54 8
5 (S)-BINOL, InCl3 0 60 46 30
a All reactions were carried out in the presence of chloroacetaldehyde (1.0 mmol),
allyltributylstannane (2.0 mmol), chiral ligands (0.22 mmol), Lewis acids
(0.2 mmol), and 4 A MS in CH2Cl2 (10 mL).
b Isolated yields.
c The ee values of 8 were determined by its benzoate derivant 9.
Table 2
Optimization of syn-epoxidation of homoallylic alcohol 8a
Entry Oxidant Solventb Time (h) Yieldc (%) drd
1 TBHP CH2Cl2 (1.0 M) 36 69 5:2
2 CHP CH2Cl2 (1.0 M) 48 67 2:1
3 UHP THF (1.0 M) 48 d d
4 NaBO3 THF (1.0 M) 48 d d
5 TBHP CH2Cl2 (0.5 M) 60 67 13:5
6 TBHP CH2Cl2 (0.1 M) 60 76 3:1
a All reactions were carried out in the presence of 8 (2.0 mmol), VO(acac)2
(0.1 mmol), oxidants (3.0 mmol), and 3 A MS at 20 C.
b In parentheses are concentration of 8.
c Isolated yields.
d The dr values were determined by 1H NMR analysis.2. Results and discussion
Our retrosynthetic approach towards 1 is depicted in Scheme 1.
It was envisaged that 1 could be derived from aldehyde 4 and
phosphonium salt 5. 4 could be accessed through a series of
transformations from syn-diol 6, which could be synthesized via
epoxy addition of 7 with sodium cyanide. Compound 7 could be
prepared by a VO(acac)2-catalyzed syn-diastereoselective epoxi-
dation of homoallylic alcohol 8. Keck enantioselective allylation of
chloroacetaldehyde with allyltributylstannane would allow for in-
troduction of the requisite 2R stereochemistry in 8.
Scheme 1. Retrosynthetic strategy for 1.Our asymmetric synthesis of rosuvastatin calcium (1) com-
mencedwith anhydrous chloroacetaldehyde,8 which was subjected
to Keck asymmetric allylation9 with allyltributylstannane in the
presence of (S)-BINOL/Ti(OiPr)4 at 20 C for 96 h furnished
homoallylic alcohol 8 in 67% yield with the desired (S)-conﬁgura-
tion, which was veriﬁed by optical rotation analysis.10 The optical
purity of 8 (94% ee) was determined byHPLC analysis of its benzoyl-
protected derivative 9 (Table 1, entry 1). (S)-VANOL/Ti(OiPr)4 and
(R)-VAPOL/Ti(OiPr)4 were screened against this reaction, but gave
very low yields (41 and 37%) and poor enantioselectivities (54 and
46% ee) (Table 1, entries 2 and 3), and the use of (S)-BINOL/FeCl3 and
(S)-BINOL/InCl3 gave even worse results (8 and 30% ee) (Table 1,
entries 4 and 5).
Many researchers have explored the syn-epoxidation of acyclic
homoallylic alcohols using a wide variety of oxidants and/or cata-
lysts,11 Of these, the VO(acac)2/tert-butyl hydroperoxide (TBHP)
oxidation system has become one of the most commonly used
systems for this transformation.11a As shown in Table 2, treatment of
8 with TBHP in the presence of 5 mol % VO(acac)2 afforded 7 in 69%
yield as an inseparable 5:2 mixture of epimers (Table 2, entry 1).After screening other oxidants, we found that the diastereoisomeric
ratio could be reduced to 2:1 using cumene hydroperoxide (CHP),
whereas the use of urea hydrogen peroxide (UHP) or sodium per-
borate proved to be ineffective (Table 2, entries 2e4). The concen-
tration of 8 was found to have a signiﬁcant impact on the
diastereoselectivity of the epoxidation, and a reduction in the con-
centration of substrate from 1.0 to 0.1 M led to a gradual increase in
the dr value (from 5:2 to 3:1) (Table 2, entries 1, 5, and 6).
With requisite epoxide 7 in hand, we proceeded to investigate
nucleophilic addition of sodium cyanide to allow for the in-
troduction of cyano group to C5 side chain. The reaction of 7 with
sodium cyanide under weakly basic conditions (pH¼7.5e8.0) pro-
ceeded smoothly to afford the desired nitrile 6 in an isolated yield
of 57%. The byproduct (3-epi-6) was also isolated in 17% yield
(Scheme 2). Subsequent Pinner reaction of 6 with a saturated so-
lution of hydrogen chloride in methanol at 0 C for 36 h afforded
a mixture of ester 10 and lactone 11 (resulting from an intra-
molecular Pinner reaction), which was used directly in next re-
action without further puriﬁcation. Protection of the mixture with
2,2-dimethoxypropane (DMP) in the presence of 10 mol % p-tol-
uenesulfonic acid gave 1,3-dioxane 12 in an overall yield of 75%
over two steps with 99% de, which was conﬁrmed by GCeMS
analysis relative to 4-epi-12 derived from 3-epi-6 (Scheme 2).
The stereochemical assignment of 12was conﬁrmed by a NOESY
study, which revealed strong NOE correlations between H-3/H-5,
H-3/H-9, and H-5/H-9. These correlations indicated that H-3, H-5,
and H-9 were on the same side of the molecule (Fig. 2).
Reaction of 12with potassium acetate or sodium benzoate in the
presence of tetrabutyl ammonium bromide furnished 13a or 13b,
respectively, in moderate yields as white solids. The optical purity
of 13 was only 95%, fortunately, it could be upgraded to 99% by
Fig. 2. The NOESY correlations of intermediate 12.
Scheme 2. Synthesis of intermediate 12.
Scheme 4. Synthesis of rosuvastatin calcium (1).
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of 85e88%. Compounds 13 were then hydrolyzed with aqueous
potassium carbonate at room temperature for 2 h to afford alcohol
14 in excellent yields. The key building block 4 was readily syn-
thesized in 73% yield by treatment of 14 with trichloroisocyanuric
acid (TCCA) in the presence of a catalytic amount of 2,2,6,6-
tetramethylpiperidinyloxy (TEMPO) (Scheme 3).12
Scheme 3. Synthesis of the key intermediate 4.Finally, Wittig oleﬁnation of 4 with phosphonium salt 53d was
performed under basic conditions (i.e., K2CO3, DMSO, 70 C) to yield
oleﬁn 15 in 72% yield. Subsequent treatment of 15 with hydro-
chloric acid (0.02 mol/L, 5 mol %) in acetonitrile at 40 C for 8 h
allowed for the deprotection of ketal to give diol 16 in 83% yield,
which was subjected to sequential hydrolysis and saliﬁcation steps
to furnish 1 in yield of 89% over two steps (Scheme 4).3d3. Conclusions
In summary, we have developed an efﬁcient 11-step sequence
for the synthesis of rosuvastatin calcium (1) starting from readily
available material chloroacetaldehyde. Keck asymmetric allylationof chloroacetaldehyde with allyltributylstannane followed by
a VO(acac)2-catalyzed stereoselective epoxidation of the resulting
homoallylic alcohol 8 allowed for rapid construction of the 3R-syn-
1,3-diol subunit of the target. Our newly developed approach is
superior to existing methodologies for preparation of 4 because it
avoids the use of Narasaka reduction. Although a large number of
synthetic strategies for 1 have already been reported in the litera-
ture, our newly developed strategy represents a unique approach
and should provide a platform for the synthesis of 1 and its
derivatives.
4. Experimental section
4.1. General
Melting points were determined on a WRS-1 digital melting
point apparatus. Optical rotations were obtained on a JASCO P1020
digital polarimeter. 1H and 13C NMR spectra were obtained on
a Bruker Avance 400 spectrometer (400, 100 MHz, respectively) in
CDCl3 or DMSO-d6 using CDCl3 (1H, d 7.26) or DMSO-d6 (1H, d 2.50)
and CDCl3 (13C, d 77.0) or DMSO-d6 (13C d 39.5) as internal stan-
dards. IR spectra were recorded on a Nicolet FTIR 4200 spectrom-
eter as KBr pellets. Mass spectra were measured on a Waters
Quattro Micromass instrument using electrospray ionization (ESI)
techniques. Enantiomeric excesses (ee) were determined by HPLC
analysis using Chiralpak columns. Unless otherwise noted all re-
actions were conducted in oven-dried glassware under inert at-
mosphere of dried Ar or N2. (S)-BINOL, (S)-VANOL, and (R)-VAPOL
were purchased from Aldrich.
4.2. (S)-1-Chloropent-4-en-2-ol (8)
Amixture of (S)-BINOL (62mg, 0.22mmol) and 4AMS (100mg)
in 5 mL anhydrous CH2Cl2 was added Ti(OiPr)4 (60 mL, 0.2 mmol).
The reaction was heated at 40 C under argon atmosphere for 1 h
before cooled to room temperature and a solution of chlor-
oacetaldehyde (1.0 mmol) in 5 mL CH2Cl2 was added. The contents
were cooled to 20 C and allyltributylstannane (0.62 mL,
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before being added saturated NaHCO3 (2 mL) and stirred at room
temperature for 2 h. The molecular sieves were removed and the
aqueous layer was extracted with CH2Cl2 (225 mL). The combined
organic extracts were dried over anhydrous Na2SO4 and evaporated
under reduced pressure (20 mmHg), then puriﬁed by column
chromatography (silica gel, EtOAc/PE, 1:15) to afford 8 (80 mg, 67%)
as a pale yellow oil and recovered (S)-BINOL (51 mg, 83%); [a]D21.1
þ4.6 (c 2.0, CHCl3, 94% ee), lit.10 [a]D25 þ5.2 (c 1.4, CHCl3); 1H NMR
(400 MHz, CDCl3) d 2.34 (m, 3H), 3.48e3.52 (m, 1H), 3.60e3.63 (m,
1H), 3.87 (m,1H), 5.13e5.19 (m, 2H), 5.76e5.86 (m,1H); MS (EI):m/
z (%)¼120 (1), 79 (100); IR (thin ﬁlm): 3379, 2951, 1645, 991 cm1.
4.3. (S)-1-Chloropent-4-en-2-yl benzoate (9)
To a stirred solution of 8 (60 mg, 0.5 mmol) and pyridine (81 mL,
1.0 mmol) in 2 mL anhydrous CH2Cl2 under argon atmosphere at
0 C was added benzoyl chloride (70 mL, 0.6 mmol). The reaction
mixture was stirred at room temperature for 3 h before being
quenched by the addition of 10 mL brine. The mixture was
extracted with 30 mL EtOAc, dried over anhydrous Na2SO4, and
concentrated under reduced pressure, then puriﬁed by column
chromatography (silica gel, PE) to afford 9 (106 mg, 95%) as a col-
orless oil; ee: 94%, determined by HPLC analysis, Daicel, Chiralpak
AD-H column (25 cm4.6 mm5 mm), n-hexane/i-propanol¼98/2,
0.3 mL/min, 254 nm, 30 C, t (major)¼16.9min, t (minor)¼17.6 min;
[a]D21.3 2.0 (c 2.0, CHCl3, 94% ee); 1H NMR (400 MHz, CDCl3) d 2.61
(t, J¼6.6 Hz, 2H), 3.73 (dd, J¼5.2, 12.0 Hz, 1H), 3.77 (dd, J¼4.8,
12.0 Hz, 1H), 5.16 (dd, J¼1.2, 10.0 Hz, 1H), 5.22 (dd, J¼1.2, 16.8 Hz,
1H), 5.30e5.36 (m, 1H), 5.77e5.87 (m, 1H), 7.45 (t, J¼7.6 Hz, 2H),
7.58 (t, J¼7.6 Hz, 1H), 8.06 (d, J¼7.6 Hz, 2H); 13C NMR (100 MHz,
CDCl3) d 35.9, 45.0, 72.5, 119.1, 128.4, 129.7, 129.9, 132.1, 133.2, 165.7;
MS (EI): m/z (%)¼224 (1), 105 (100); HRMS (ESI-TOF) m/z calcd for
C12H14ClO2 (MþHþ) 225.0677, found 225.0679; IR (thin ﬁlm): 2926,
1723, 1271, 992, 706 cm1.
4.4. (2S)-1-Chloro-3-(oxiran-2-yl)propan-2-ol (7)
Amixture of 8 (240mg, 2.0mmol), VO(acac)2 (26mg, 0.1mmol),
and 3 A MS (100 mg) in 20 mL anhydrous CH2Cl2 was added TBHP
(0.9 mL, 3.3 M in toluene)13 under argon atmosphere at 0 C. The
reaction was stirred at 20 C for 60 h before being quenched by the
addition of 10 mL saturated sodium sulﬁte. The molecular sieves
were removed and the aqueous layer was extracted with CH2Cl2
(330 mL). The combined organic extracts were dried over anhy-
drous Na2SO4 and evaporated under reduced pressure, then puri-
ﬁed by column chromatography (silica gel, EtOAc/PE, 1:4) to afford
714 (colorless oil, 207 mg, 76%) as an inseparable 3:1 mixture of
epimers. syn-isomer: 1H NMR (400 MHz, CDCl3) d 1.60 (ddd, J¼6.8,
14.0, 21.6 Hz, 1H), 1.87 (dt, J¼4.4, 14.0 Hz, 1H), 2.46 (dd, J¼2.8,
4.4 Hz, 1H), 2.71 (t, J¼4.4 Hz, 1H), 3.02 (m, 1H), 3.34 (br s, 1H),
3.49e3.57 (m, 2H), 3.96 (m, 1H); anti-isomer: 1H NMR (400 MHz,
CDCl3) d 1.46 (ddd, J¼4.0, 7.6, 14.4 Hz, 1H), 1.95 (dt, J¼4.4, 14.0 Hz,
1H), 2.49 (dd, J¼2.8, 4.4 Hz, 1H), 2.75 (t, J¼4.4 Hz, 1H), 3.06 (m, 1H),
3.34 (br s, 1H), 3.40e3.57 (m, 2H), 3.93e3.95 (m, 1H); MS (EI): m/z
(%)¼135 (1), 57 (100); IR (thin ﬁlm): 3396, 2955, 1719, 1641 cm1.
4.5. (5S)-6-Chloro-3,5-dihydroxyhexanenitrile (6 and 3-epi-6)
To a stirred solution of 7 (6.8 g, 50 mmol) in 10 mL water at 0 C
was added dropwise a solution of sodium cyanide (2.94 g,
60 mmol) in 15 mL water maintained pH¼7.5e8.0 by saturated
citric acid. The reaction was stirred at 30 C for 42 h and the
aqueous layer was extractedwith EtOAc (5100mL). The combined
organic extracts were dried over anhydrous Na2SO4 and evaporated
under reduced pressure, then puriﬁed by column chromatography(silica gel, EtOAc/PE, 1:1) to afford 6 (4.64 g, 57%) as a pale yellow oil
and 3-epi-6 (1.38 g, 17%) as a white solid. 6: [a]D28.1 þ3.4 (c 5.0,
CHCl3); 1H NMR (400 MHz, CDCl3) d 1.73e1.83 (m, 2H), 2.55 (dd,
J¼6.0, 16.8 Hz, 1H), 2.62 (dd, J¼4.8, 16.8 Hz, 1H), 3.50 (dd, J¼6.0,
11.2 Hz, 1H), 3.56 (dd, J¼4.4, 11.2 Hz, 1H), 3.98 (br s, 1H), 4.06 (m,
1H), 4.17 (m, 1H), 4.40 (br s, 1H); 13C NMR (100 MHz, CDCl3) d 26.0,
38.9, 49.1, 66.6, 70.6, 117.7; MS (EI): m/z (%)¼163 (1), 68 (100);
HRMS (ESI-TOF)m/z calcd for C6H935ClNO2 (MH) 162.0316, found
162.0312; IR (thin ﬁlm): 3400, 2256, 1723, 1641, 974 cm1. 3-epi-6:
mp 46e48 C; [a]D28.4 30.6 (c 1.0, CHCl3); 1H NMR (400 MHz,
DMSO-d6) d 1.43e1.50 (m, 1H), 1.57e1.66 (m, 1H), 2.56 (dd, J¼6.0,
16.8 Hz, 1H), 2.65 (dd, J¼4.8, 16.8 Hz, 1H), 3.51 (dd, J¼5.2, 11.2 Hz,
1H), 3.56 (dd, J¼4.8, 11.2 Hz, 1H), 3.80e3.87 (m, 1H), 3.89e3.96 (m,
1H), 5.09 (d, J¼5.6 Hz, 1H), 5.27 (d, J¼5.6 Hz, 1H); 13C NMR
(100MHz, DMSO-d6) d 26.1, 40.8, 50.3, 63.2, 66.8,119.1; MS (EI):m/z
(%)¼163 (1), 68 (100); HRMS (ESI-TOF) m/z calcd for C6H935ClNO2
(MH) 162.0316, found 162.0310; IR (thin ﬁlm): 3392, 2955, 2252,
1413, 930 cm1.
4.6. Methyl 2-((6S)-6-(chloromethyl)-2,2-dimethyl-1,3-
dioxan-4-yl) acetate (12 and 4-epi-12)
To a stirred solution of 6 (3.3 g, 20 mmol) in 40mL dry methanol
saturated with hydrogen chloride under argon atmosphere was
reacted at 0 C for 36 h before being quenched by saturated NaHCO3
solution. The methanol was evaporated under reduced pressure
and the aqueous layer was extractedwith ethyl acetate (3100mL).
The combined organic extracts were dried over anhydrous Na2SO4
and evaporated under reduced pressure to afford a mixture of 10
and 11 that was pure enough to be used in next step. To a stirred
solution of a mixture of 10 and 11 and 2,2-dimethoxypropane
(12 mL, 100 mmol) in 50 mL acetone under argon atmosphere at
room temperature was added 4-methylbenzenesulfonic acid
monohydrate (380 mg, 2.0 mmol). The mixture was stirred at room
temperature for 16 h before being quenched by the addition of
0.3 mL triethylamine and removed solvent under reduced pressure.
the residue was puriﬁed by column chromatography (silica gel,
EtOAc/PE, 1:8) to afford 12 (pale yellow oil, 75% from 6); di-
astereomeric excess: 99%, tR¼14.2 min, the de value was measured
by GCeMS: Agilent, HP-5MS column (30 m0.25 mm0.25 mm),
injector temperature: 280 C, oven temperature program from
50 C (2 min) to 280 C at 10 C/min, carrier gas: He, ﬂow rate:
0.9mL/min, ionization energy 70 eV in the electronic ionization (EI)
mode; [a]D28.3 þ3.3 (c 2.0, CHCl3); 1H NMR (400 MHz, CDCl3) d 1.21
(dt, J¼11.6, 12.8 Hz, 1H), 1.35 (s, 3H), 1.43 (s, 3H), 1.75 (dt, J¼2.4,
12.8 Hz, 1H), 2.38 (dd, J¼6.0, 15.6 Hz, 1H), 2.54 (dd, J¼6.8, 15.6 Hz,
1H), 3.36 (dd, J¼6.0, 11.2 Hz, 1H), 3.48 (dd, J¼5.6, 11.2 Hz, 1H), 3.65
(s, 3H), 4.01e4.07 (m, 1H), 4.27e4.33 (m, 1H); 13C NMR (100 MHz,
CDCl3) d 19.6, 29.7, 33.8, 40.9, 46.9, 51.6, 65.5, 69.0, 99.2, 171.0; MS
(EI): m/z (%)¼221 (100), 59 (90); IR (thin ﬁlm): 2994, 1737, 988,
950 cm1.
4-epi-12 was prepared by the similar procedure of 12: (pale
yellow oil, 73% from 3-epi-6); 99% de, tR¼13.6 min; [a]D22.4 23.5 (c
1.0, CHCl3); 1H NMR (400 MHz, CDCl3) d 1.34 (s, 3H), 1.37 (s, 3H),
1.71 (ddd, J¼6.4, 9.6, 12.8 Hz, 1H), 1.80 (ddd, J¼6.0, 9.2, 12.8 Hz, 1H),
2.45 (dd, J¼5.2, 15.6 Hz, 1H), 2.55 (dd, J¼8.4, 15.6 Hz, 1H), 3.46e3.54
(m, 2H), 3.67 (s, 3H), 3.98e4.05 (m, 1H), 4.24e4.31 (m, 1H); 13C
NMR (100 MHz, CDCl3) d 24.4, 24.6, 35.3, 40.3, 46.7, 51.6, 63.3, 66.8,
101.1, 171.1; MS (EI):m/z (%)¼221 (100), 59 (80); HRMS (ESI-TOF)m/
z calcd for C10H17ClNaO4 (MþNaþ) 259.0707, found 259.0701; IR
(thin ﬁlm): 2990, 2955, 1740, 1440, 999 cm1.
4.7. General procedure for synthesis of 13
To a stirred solution of 12 (710 mg, 3 mmol), potassium acetate
or sodium benzoate (15 mmol), and TBAB (966 mg, 3 mmol) in
X. Chen et al. / Tetrahedron 70 (2014) 5794e5799579820 mL DMF under argon atmosphere was heated to 100 C for 24 h
before added 150 mL petroleum ether. The organic phase was
washed with water (320 mL) and brine (320 mL), then dried
over anhydrous Na2SO4, and evaporated under reduced pressure.
The residue was puriﬁed by column chromatography (silica gel,
EtOAc/PE, 1:15) to afford 13. 13a:6c (white solid, 453 mg, 58%), mp
48e49 C (n-heptane), lit.6c mp 49e50 C; The ee value of 13awas
upgraded to over 99% by recrystallization using n-heptane (re-
covered yield: 85%) and determined by HPLC analysis of its derivant
13b, Daicel, Chiralpak OD-H column (25 cm4.6 mm5 mm), n-
hexane/i-propanol¼90/10, 0.3 mL/min, 254 nm, 30 C, t (major)¼
21.0 min, t (minor)¼26.5 min; [a]D12.2 þ16.2 (c 1.0, CHCl3, 99% ee),
lit.6c [a]Dþ12 (c 0.92, CHCl3); 1H NMR (400MHz, CDCl3) d 1.19e1.28
(m, 1H), 1.36 (s, 3H), 1.44 (s, 3H), 1.57 (dt, J¼2.0, 12.4 Hz, lH), 2.05 (s,
3H), 2.38 (dd, J¼6.0, 15.6 Hz, 1H), 2.54 (dd, J¼6.8, 15.6 Hz, 1H), 3.66
(s, 3H), 3.96e4.05 (m, 2H), 4.06e4.11 (m, 1H), 4.28e4.34 (m, 1H);
MS (EI): m/z (%)¼245 (70), 59 (100); IR (KBr): 3002, 2959, 1736,
1719, 1460, 941 cm1. 13b:7e (white solid, 492 mg, 51%), mp
80e81 C (n-heptane); The ee value of 13bwas upgraded from 95%
to over 99% by recrystallization using n-heptane (recovered yield:
88%) and determined by HPLC analysis, Daicel, Chiralpak OD-H
column (25 cm4.6 mm5 mm), n-hexane/i-propanol¼90/10,
0.3 mL/min, 254 nm, 30 C, t (major)¼21.0 min, t (minor)¼
26.5 min; [a]D12.8 þ5.7 (c 1.0, CHCl3, 99% ee), lit.7e [a]D20 þ2.4 (c 0.9,
CHCl3, 98% ee); 1H NMR (400 MHz, CDCl3) d 1.32e1.40 (m, 1H), 1.40
(s, 3H), 1.48 (s, 3H), 1.68 (dt, J¼2.0, 12.4 Hz, lH), 2.42 (dd, J¼6.0,
15.6 Hz,1H), 2.58 (dd, J¼6.8,15.6 Hz,1H), 3.68 (s, 3H), 4.25e4.31 (m,
1H), 4.28 (s, 2H), 4.33e4.40 (m, 1H), 7.43 (t, J¼7.6 Hz, 2H), 7.55 (t,
J¼7.6 Hz, 1H), 8.04 (d, J¼7.6 Hz, 2H); MS (EI):m/z (%)¼307 (30), 105
(100); IR (KBr): 2980, 1730, 1712, 991, 945 cm1.
4.8. Methyl 2-((4R,6S)-6-(hydroxymethyl)-2,2-dimethyl-1,3-
dioxan-4-yl)acetate (14)
To a stirred solution of 13 (2 mmol) in 5 mL methanol and 2 mL
water at 0 C was added potassium carbonate (690 mg, 5 mmol).
The reaction mixture was stirred at room temperature for 2 h be-
fore being quenched by the addition of NH4Cl. The methanol was
evaporated under reduced pressure and the aqueous layer was
extracted with EtOAc (350 mL), dried over anhydrous Na2SO4,
ﬁltered, and concentrated under reduced pressure, then puriﬁed by
column chromatography (silica gel, EtOAc/PE, 1:2) to afford 14 as
colorless oil (yields: 85% from 13a, 83% from 13b); [a]D15.2þ9.9 (c 2.0,
CHCl3), lit.6c [a]D þ9.7 (c 1.9, CHCl3); 1H NMR (400 MHz, CDCl3)
d 1.21e1.34 (m, 1H), 1.37 (s, 3H), 1.46 (s, 3H), 1.50 (dt, J¼2.4, 12.4 Hz,
lH), 2.19 (br s, 1H), 2.38 (dd, J¼6.0, 15.6 Hz, 1H), 2.55 (dd, J¼7.2,
15.6 Hz, 1H), 3.45e3.50 (m, 1H), 3.55e3.62 (m, 1H), 3.67 (s, 3H),
3.98e4.02 (m, 1H), 4.30e4.36 (m, 1H); MS (EI):m/z (%)¼217 (1), 59
(100); IR (thin ﬁlm): 3460, 2994, 1737, 1084, 992 cm1.
4.9. Methyl 2-((4R,6S)-6-formyl-2,2-dimethyl-1,3-dioxan-4-yl)
acetate (4)
To a stirred solution of 14 (654 mg, 3 mmol), TEMPO (5 mg,
0.03 mmol), and NaHCO3 (2.0 g, 24 mmol) in 15 mL CH2Cl2 and
15mLwater at 0 Cwas added TCCA (852mg, 90% purity, 3.3 mmol)
in batches. The reaction mixture was stirred at 0 C for 1 h before
being extracted with CH2Cl2 (350 mL). The combined organic
extracts were dried over anhydrous Na2SO4 and evaporated under
reduced pressure to afford 4 as a pale yellow oil (473 mg, 73%) that
was pure enough to be used in next step; [a]D13.315.9 (c 1.0, CHCl3),
lit.7b [a]D 14.9 (c 1.0, CHCl3); 1H NMR (400 MHz, CDCl3)
d 1.29e1.39 (m, 1H), 1.44 (s, 3H), 1.48 (s, 3H), 1.84 (dt, J¼2.4, 12.8 Hz,
lH), 2.42 (dd, J¼6.0, 15.6 Hz, 1H), 2.57 (dd, J¼6.8, 15.6 Hz, 1H), 3.68
(s, 3H), 4.28e4.38 (m, 2H), 9.57 (s, 1H); MS (EI): m/z (%)¼201 (30),
59 (100); IR (thin ﬁlm): 2994, 2952, 1736, 1440, 999 cm1.4.10. Methyl 2-((4R,6S)-6-((E)-2-(4-(4-ﬂuorophenyl)-6-
isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)vi-
nyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate (15)
To a stirred solution of 4 (298 mg, 1.38 mmol), 5 (849 mg,
1.25mmol), and potassium carbonate (173mg,1.25mmol) in 10 mL
anhydrous DMSO under argon atmosphere was heated to 70 C for
3 h before added 100 mL EtOAc. The organic phase was washed
with water (320 mL) and brine (20 mL), then dried over anhy-
drous Na2SO4, and evaporated under reduced pressure. The residue
was puriﬁed by column chromatography (silica gel, EtOAc/PE, 1:12)
to afford 15 (482mg, 72%) as awhite solid; mp 122e124 C, lit.15 mp
130e132 C; [a]D12.3 þ5.6 (c 1.0, CHCl3); 1H NMR (400 MHz, CDCl3)
d 1.09e1.21 (m, 1H), 1.26 (d, J¼6.8 Hz, 3H), 1.27 (d, J¼6.8 Hz, 3H),
1.40 (s, 3H), 1.49 (s, 3H), 1.53e1.58 (m, 1H), 2.38 (dd, J¼6.4, 16.0 Hz,
1H), 2.57 (dd, J¼6.4, 16.0 Hz, 1H), 3.37 (hept, J¼6.8 Hz, 1H), 3.51 (s,
3H), 3.57 (s, 3H), 3.70 (s, 3H), 4.29e4.36 (m, 1H), 4.41e4.45 (m, 1H),
5.46 (dd, J¼5.6, 16.0 Hz, 1H), 6.52 (d, J¼16.0 Hz, 1H), 7.08 (t,
J¼8.4 Hz, 2H), 7.64 (dd, J¼5.2, 8.0 Hz, 2H); MS (ESI): m/z¼536
(MþHþ), 558 (MþNaþ); IR (KBr): 2996, 2951,1739,1600,1442,1152,
968, 848 cm1.
4.11. (3R,5S,E)-Methyl 7-(4-(4-ﬂuorophenyl)-6-isopropyl-2-
(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-
dihydroxyhept-6-enoate (16)
To a stirred solution of 15 (268 mg, 0.5 mmol) in 5 mL aceto-
nitrile at 40 C was added hydrochloric acid (1.25 mL, 0.02 M,
0.025 mmol) dropwise. The reaction mixture was stirred at 40 C
for 8 h before being quenched by Et3N and removed solvent under
reduced pressure. The residue was puriﬁed by column chroma-
tography (silica gel, EtOAc/PE, 1:1) to afford 1616 (205 mg, 83%) as
a colorless spumy solid; [a]D13.5 4.7 (c 1.0, CHCl3); 1H NMR
(400 MHz, CDCl3) d 1.26 (d, J¼6.8 Hz, 6H), 1.35e1.60 (m, 2H),
2.43e2.51 (m, 2H), 3.36 (hept, J¼6.8 Hz, 1H), 3.51 (s, 3H), 3.56 (s,
3H), 3.72 (s, 3H), 4.21 (m, 1H), 4.45 (m, 1H), 5.46 (dd, J¼5.2, 16.0 Hz,
1H), 6.63 (d, J¼16.0 Hz, 1H), 7.08 (t, J¼8.4 Hz, 2H), 7.63 (dd, J¼6.0,
8.0 Hz, 2H); 13C NMR (100 MHz, CDCl3) d 21.6, 21.6, 32.1, 33.1, 41.1,
41.8, 42.4, 51.9, 68.4, 71.9, 115.0 (d, JCeF¼21.5 Hz), 121.4, 122.7, 132.1
(d, JCeF¼8.3 Hz), 134.5 (d, JCeF¼3.2 Hz), 139.3, 157.2, 163.2 (d,
JCeF¼248.2 Hz), 163.5, 172.9, 174.9; MS (ESI):m/z¼496 (MþHþ), 518
(MþNaþ); IR (KBr): 3462, 2966, 2931, 2871, 1732, 1548, 1438, 1386,
1152, 964, 840, 795 cm1.
4.12. Rosuvastatin calcium (1)
To a stirred solution of 16 (149 mg, 0.3 mmol) in MeOH (2mL) at
0 C was added NaOH (0.36 mL, 1.0 M, 0.36 mmol), then reacted at
0 C for 1 h before being added the solution of CaCl2 (1.5 mL, 0.2 M,
0.3mmol). Themixturewas stirred at 20 C for 0.5 h before ﬁltrated
the resulting white slurry, washed, and dried in vacuum to afford 1
(133 mg, 89%) as a white powder; mp 145e149 C, lit.17 mp
145e150 C; [a]D14.5 7.3 (c 0.5, CHCl3); 1H NMR (400 MHz, CDCl3)
d 1.20 (d, J¼6.0 Hz, 6H), 1.28e1.36 (m, 1H), 1.47e1.54 (m, 1H),
1.97e2.03 (m, 1H), 2.12e2.16 (m, 1H), 3.36e3.43 (m, 1H), 3.43 (s,
3H), 3.54 (s, 3H), 3.76 (m, 1H), 4.20 (m, 1H), 5.52 (dd, J¼5.6, 16.0 Hz,
1H), 6.50 (d, J¼16.0 Hz, 1H), 7.27 (t, J¼8.4 Hz, 2H), 7.70 (dd, J¼6.0,
8.0 Hz, 2H); MS (ESI): m/z¼482 (acid, MþHþ), 504 (acid, MþNaþ);
IR (KBr): 3376, 2973, 2931, 2875, 1604, 1548, 1442, 1073, 968, 844,
776 cm1.
Supplementary data
Copies of 1H, 13C NMR, HPLC, and GCeMS spectra for the com-
pounds. Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.tet.2014.06.077.
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